IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 64

Change

-0.79 (-1.22)%

Market Cap

N/A

Volume

0.10M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-2.92 (-2.16%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-1.32 (-2.08%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-2.59 (-2.69%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

-1.08 (-1.43%)

USD 0.16B
IDNA iShares Genomics Immunology an..

+0.04 (+0.21%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-3.90 (-4.14%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.37 (+1.40%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.37 (-1.47%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-0.39 (-0.73%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.53 (+3.19%)

USD 0.01B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.62% 86% B+ 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.62% 86% B+ 63% D
Trailing 12 Months  
Capital Gain 1.18% 81% B- 59% D-
Dividend Return 1.03% 88% B+ 21% F
Total Return 2.21% 81% B- 49% F
Trailing 5 Years  
Capital Gain 29.61% 67% D+ 49% F
Dividend Return 9.19% 100% F 20% F
Total Return 38.79% 86% B+ 41% F
Average Annual (5 Year Horizon)  
Capital Gain 3.05% 57% F 47% F
Dividend Return 4.44% 67% D+ 44% F
Total Return 1.39% 100% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 14.40% 62% D 66% D+
Risk Adjusted Return 30.80% 67% D+ 47% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike